Amgen and Mirati cancer drug push despite KRAS failures
Business Insider,
This story requires our BI Prime membership. To read the full article, simply click here to claim your deal and get access to…
This story requires our BI Prime membership. To read the full article, simply click here to claim your deal and get access to…
Pharmaceutical companies long wanted to develop a drug that would target KRAS, a common gene mutation seen in cancers.